Tiziana Life Sciences (TLSA)

Executive Summary

Tiziana Life Sciences is a clinical-stage biotechnology company pioneering intranasal foralumab, an anti-CD3 monoclonal antibody designed to modulate the immune system and address neuroinflammation in neurodegenerative diseases. Unlike systemic therapies, intranasal delivery targets the brain directly, potentially reducing side effects. The company's lead program is in non-active secondary progressive multiple sclerosis (na-SPMS), a disease with high unmet need, where Phase 2 trials are actively recruiting. Tiziana is also advancing foralumab in Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA), leveraging its platform to treat multiple indications. Additionally, the company has an oral CDK inhibitor, milciclib, in Phase 2 for non-small cell lung cancer (NSCLC). Recent milestones include the initiation of multiple Phase 2 trials for foralumab, with top-line data expected in late 2026. Tiziana's focused strategy on intranasal delivery and its broad pipeline position it as a compelling player in neuroimmunology. However, the company remains pre-revenue and faces typical clinical-stage risks. Success in the upcoming foralumab trials could validate its platform and unlock significant value, while failures would pose major setbacks. The upcoming catalysts are critical for the company's trajectory.

Upcoming Catalysts (preview)

• Q3 2026Topline Phase 2 data for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS)60% success
• Q4 2026Topline Phase 2 data for intranasal foralumab in Alzheimer's disease / mild cognitive impairment40% success
• TBDUpdate on Phase 2 trial of milciclib in NSCLC (trial completion overdue, potential data release)50% success